BEYFORTUS
nirsevimab
- Strength
- 100 mg/mL
- Form
- Injection
- Class
- Respiratory Syncytial Virus Anti-F Prot…
Sanofi Vaccines US Inc.
Not stocked by us — reference only
nirsevimab
Listed by Sanofi Vaccines US Inc.
| Dosage form | Injection |
|---|---|
| Route | Intramuscular |
| Drug class | Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody |
| Approval route | BLA — biologic licence |
| NDC code | 49281-574 |
| FDA application | BLA761328 |
| RxNorm concept | 2642406 |
| Package sizes listed | 2 |
| Marketed since | July 2023 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
nirsevimab
Sanofi Vaccines US Inc.
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.